19 Feb Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
Posted at 00:00h
in
Authored by: Hankins Catherine
In: Expert Review of Pharmacoeconomics & Outcomes Research, 2014, Feb 19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/24552641
http://informahealthcare.com/doi/abs/10.1586/14737167.2014.887447